The in vitro adhesion of Candida albicans to buccal epithelial cells (BEC) from diabetic and non-diabetic individuals after in vivo and in vitro application of nystatin.
Buccal epithelial cells (BEC) from 12 patients with diabetes mellitus and 12 age- and sex-matched non-diabetic subjects were tested in vitro for adhesion of Candida albicans following exposure to nystatin both in vitro and in vivo. Adhesion was significantly reduced (P < 0.002) to cells from both the diabetic and non-diabetic subjects after in vitro exposure to nystatin, but the reduction in adhesion was variable (5.0-50.7% in control subjects and 0.5-48.4% in diabetic subjects) and equivalent between the two groups. In vivo exposure to nystatin produced no overall significant reduction in candidal adhesion to cells from either diabetic or control subjects.
Darwazeh
A M
AM
Department of Oral Medicine and Periodontology, Faculty of Dentistry, Jordan University of Science and Technology, Irbid, Jordan.
MacFarlane
T W
TW
Lamey
P J
PJ
D000328:Adult; D000935:Antifungal Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002176:Candida albicans / Q000187:drug effects* / Q000502:physiology; D002180:Candidiasis, Oral / Q000150:complications / Q000188:drug therapy; D016022:Case-Control Studies; D002448:Cell Adhesion / Q000187:drug effects* / Q000502:physiology; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000382:microbiology* / Q000503:physiopathology; D004847:Epithelial Cells; D004848:Epithelium / Q000382:microbiology; D005260:Female; D006801:Humans; D008297:Male; D009061:Mouth Mucosa / Q000382:microbiology*; D009761:Nystatin / Q000494:pharmacology* / Q000627:therapeutic use
D000935:Antifungal Agents; D009761:Nystatin